Universal Genetic Testing for Cancer Risk Reduction
ConditionGenetic Testing
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age25-39
SponsorNYU Langone Health
About this trial
The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.
Eligibility criteria
Qualifiers
Female patients between ages of 25-39 years at the time of visit
Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol.
Disqualifiers
Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers
Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable)
History of bilateral salpingo-oophorectomy
Visit related to pregnancy or immediately postpartum (within 2 weeks)
Trial design
Treatments tested in this trial
- Natera® Empower™ hereditary cancer panel test
- Specialist Referral
Treatment groups
600 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov